Texas Valley Clinical Research

What Texas Valley Clinical Research does

Texas Valley Clinical Research (TVCR) is a private clinical research organization founded in 2022 and headquartered in Weslaco, Texas, that conducts Phase II-IV clinical trials for sponsors across metabolic, cardiovascular, endocrine, and neurologic therapeutic areas including Type 1 and Type 2 diabetes, adult and pediatric obesity, cardiovascular risk, Alzheimer's prevention, hypothyroidism, and Prader-Willi Syndrome. The organization operates from clinical sites in Weslaco and Mission within the Rio Grande Valley, with a third location announced for San Antonio in 2026, and equips those sites with laboratory capabilities including PK sampling, MMTT/OGTT testing, genetic sampling, IP infusions, and a third-party imaging partner network, plus a community-facing DEXA scanning service launched in April 2026 offering bone density and body composition scans to consumers for $125-$250 without insurance or physician referral.

Revenue is generated primarily through fee-for-service clinical trial contracts with pharmaceutical, biotechnology, and other sponsors, supplemented by the self-pay consumer DEXA scan service. Patient acquisition is community-led and bilingual: 100% of full-time coordinators speak English and Spanish, the firm sponsors local events such as Texas Onion Fest and Alfresco Weslaco, and patient recruitment targets the predominantly Hispanic Rio Grande Valley population — a demographic that constitutes less than 1% of U.S. clinical trial participation despite geographic concentration — supported by a co-located clinical referral relationship with Dr. Eduardo Luna's Valley Diabetes and Endocrinology Center (VDECC) and a sponsorship of STJDA's Camp Freedom diabetes camp.

Operations are led by CEO and Director of Research Preston Hale, RN, with Dr. Eduardo Luna serving as Principal Investigator across multiple protocols, a sub-investigator team that includes board-certified endocrinologists, three ACRP-CCRC-certified clinical research coordinators, and a regulatory affairs function. TVCR cites a 99% patient retention rate during study duration and 1-2 day data entry response times as execution differentiators, along with HIPAA-compliant handling of participant health information. The firm is privately held with no disclosed funding rounds, no parent company, and no publicly disclosed revenue.

Name

Texas Valley Clinical Research

Legal name

Texas Valley Clinical Research

Website

https://tvcrtrials.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Texas Valley Clinical Research is a private, community-rooted clinical research organization founded in 2022 that conducts Phase II-IV clinical trials in diabetes, obesity, cardiovascular, and neurologic conditions for pharmaceutical and biotechnology sponsors across South Texas, with a bilingual, predominantly Hispanic patient base in the Rio Grande Valley.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (6215)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

akta.pro secondary industry

Clinical Trial Monitoring Support (On-site/Remote) (HLAGACAG)

Keywords

• Clinical trial services
• Clinical research organization
• Metabolic disease trials
• Endocrine clinical studies
• DEXA scanning services

Headquarters

HQ city

Weslaco

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel

Revenue model

1. Clinical Trial Conduct: TVCR conducts clinical trials on behalf of pharmaceutical, biotechnology, and other organizations. Revenue is generated through study agreements with sponsors who pay for research services, data collection, and participant management. The company was founded in 2022 and has been strengthening relationships with sponsors and securing agreements for ongoing and future studies.
2. DEXA Scanning Services: Self-pay wellness service offering DEXA scans to community members outside of clinical trial settings. Cash-pay service with no insurance or physician referral required. Three scan options available: Bone Density ($125), Body Composition ($125), and Combined Report ($250).

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Texas Valley Clinical Research (TVCR) is a clinical research organization that conducts Phase II-IV clinical trials across metabolic, cardiovascular, endocrine, and neurologic therapeutic areas including type 2 diabetes, type 1 diabetes, obesity, cardiovascular risk, Alzheimer's prevention, hypothyroidism, and Prader-Willi Syndrome. The company enrolls patients from the Rio Grande Valley community under sponsor agreements with pharmaceutical and biotechnology organizations, providing fully equipped research facilities with laboratory and imaging capabilities. It also offers self-pay DEXA scanning services (bone density and body composition) directly to community members.

Product overview

Texas Valley Clinical Research operates as a clinical research organization conducting clinical trials across multiple therapeutic areas. Their core offering is clinical trial participation opportunities for the Rio Grande Valley community. They provide DEXA scanning as a separate diagnostic wellness service available to the general public. The organization operates from two locations in Weslaco and Mission, Texas, with expansion to San Antonio announced. Their therapeutic focus areas include diabetes (Type 1 and Type 2), obesity (pediatric and adult), cardiovascular risk, Alzheimer's prevention, hypothyroidism, and Prader-Willi Syndrome.

Differentiator

Problem solved

Functional benefit

Products and services

• Type 2 Diabetes Clinical Studies

Quantifiable outcome

• 99% patient retention rate during study duration
• +4 more outcomes

Named customers6 records

Segments6 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature1 record

Partnerships

Three partnerships are on record, tiered core and minor.

• Valley Diabetes and Endocrinology Center (VDECC)coreStrategic or Co-development PartnerDr. Eduardo Luna's practice, VDECC, is co-located in the same building as TVCR in Weslaco. This facilitates seamless experience for study participants and enables close collaboration between clinical care and research operations. Dr. Luna serves as Principal Investigator for multiple TVCR studies.
• STJDA (South Texas Juvenile Diabetes Association)minorStrategic or Co-development PartnerTVCR sponsors STJDA's Camp Freedom-Residential, an overnight camp for children ages 6-14 living with diabetes in the Rio Grande Valley. Mayra Cantazaro, TVCR Sub-Investigator, serves as VP of STJDA.
• Weslaco Economic Development CorporationminorOthersPartnership for community events including Alfresco Weslaco street festivals. TVCR serves as Platinum Sponsor for these community celebrations.

Scale indicators7 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• Fortrea (formerly Labcorp Drug Development): Fortrea was spun off from Labcorp in 2023 as a standalone CRO providing clinical trial services across all phases. It operates a large site network and competes for sponsor trial placements in the same therapeutic areas TVCR serves.
• ICON plc: ICON plc is a global CRO offering site management, full-service trial execution, and laboratory services. Following its PRA Health Sciences acquisition, ICON operates one of the largest site networks in the industry, comparable to TVCR's site-based model but at vastly greater scale and geographic breadth.
• IQVIA: IQVIA is the world's largest CRO and clinical research site network operator, with extensive reach in diabetes, obesity, and cardiometabolic trials. It competes with TVCR for sponsor study allocations and has the scale to win preferred-partner status that could squeeze smaller independent sites.
• Syneos Health: Syneos Health is a fully integrated biopharmaceutical solutions organization offering both clinical development and commercial services. Its Clinical Solutions segment operates a large site network and competes for trial allocations across metabolic and cardiovascular indications.

Direct peers

• Medpace: Medpace is a mid-sized, full-service CRO with strong therapeutic focus in metabolic, cardiovascular, and endocrine indications — directly overlapping TVCR's core study areas. As a CRO with in-house site relationships, Medpace represents both a sponsor customer and a competitor for trial execution.
• ClinChoice: ClinChoice is a global CRO providing clinical trial management, biometrics, and site support services. It competes for sponsor trial execution work in metabolic and cardiovascular indications and represents both a partner and competitor for smaller independent sites like TVCR.
• Accel Research Sites: Accel Research Sites operates a network of multi-specialty clinical research sites across the U.S., focusing on therapeutic areas such as metabolic disease, neurology, and vaccines. It competes with TVCR for sponsor study placements and shares the model of physician-embedded community-based trial delivery.
• Velocity Clinical Research: Velocity Clinical Research is one of the largest integrated clinical research site organizations in the U.S., operating dozens of multi-therapeutic sites. It is directly comparable to TVCR as a multi-site, sponsor-facing research organization competing for the same Phase II-IV study allocations, albeit at much larger scale.
• Alliance for Multispecialty Research (AMR): AMR is a network of independent, community-based clinical research sites conducting Phase I-IV trials across multiple therapeutic areas. It is highly comparable to TVCR as a multi-site, sponsor-facing research organization, with similar physician-embedded operational model.

Emerging players

• ProSciento: ProSciento is a clinical research organization specializing in early-phase metabolic disease clinical research, including diabetes, obesity, and NASH. It is directly comparable to TVCR's therapeutic focus and shares a translational-research, sponsor-facing model, though it emphasizes earlier-phase work.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/tvcrtrials
• LinkedInlinkedin.com/company/texas-valley-clinical-research

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Texas Valley Clinical Research